What’s next for the biotechnology market?

biotechnology
© iStcok/Kkolosov

SciTech Europa welcomes Sumant Ugalmugale to discuss Global Market Insight’s new study which predicts the growth of the biotechnology market.

Biotechnology Market size was valued at $417bn (~€376.2bn)in 2018 and is expected to witness 8.3% CAGR from 2019 to 2025. Touted to be one of the most pronounced verticals of the healthcare space, biotechnology market share, as claimed by experts, is all set to soar with numerous growth avenues springing by the day. The industry undeniably deserves credit for having brought forth numerous astounding products that have bolstered the quality of human life and solved integral problems. The global biotechnology market is projected to record a highly commendable y-o-y growth rate ahead, owing to the surging incidences of chronic conditions such as cardiac disorders, cancer,  diabetes, and others across the globe.

Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis:

  1. Abbott Laboratories
  2. Agilent Technologies, Inc.
  3. Amgen Inc
  4. Biogen Scientific
  5. Dexcom Inc.
  6. Bio-Rad Laboratories, Inc.
  7. Danaher Corporation
  8. Hoffmann-La Roche Ltd.

Logically speaking, as the burden of these diseases increases it becomes imperative to combat them on scale, and that is where biotechnology comes into play. From genetically modified foods to diagnostic & preventative agents to environmental products and bio-based pest control, biotechnology is ubiquitous and plays a prominent role everywhere.

Key players operating in the global biotechnology market are F. Hoffmann-La Roche, Abbott Laboratories, Amgen, Agilent Technologies, BioGen Medical Instruments, PerkinElmer, Danaher, Illumina, Merck, Qiagen, Bio-Rad Laboratories, and Thermo Fisher Scientific. These key players implement strategic initiatives such as new product launch, geographical expansion, mergers and acquisitions to fortify their product suite and boost their standing in the market. A recent instance providing validation to the above claim is of Staten Biotechnology which has entered into a collaboration agreement with Novo Nordisk to jointly develop preclinical dyslipidemia candidate of Staten – STT-5058.

Following is a precise summary of the top companies making a difference to the dynamics of biotechnology market:

Merck leverages the power of Cyclica’s Ligand Express

Merck, a pharma major, has reportedly signed a licensing contract with Cyclica Incorporation for utilising Ligand Express, a cloud-powered in silico proteome screening platform. Reportedly, Ligand Express is an AI augmented structural proteome screening platform being used to unleash new targets which are designed to interact with a small molecule.

The one year agreement will permit Merck to efficiently and quickly expound mechanisms of action, assess safety profiles, and discover further applications for numerous under-trial small molecules, including those acknowledged in highly disease-related phenotypic screens.

Abbott seeks new acquisition to develop treatment for diseased mitral valves

Abbott has reportedly exercised its option to acquire Cephea Valve Technologies Incorporation, a medical device maker fabricating a minimally-invasive cardiac valve replacement technology for patients suffering with mitral valve disease. This acquisition would further augment Abbott’s pinnacle position in the therapies market for mitral valve disease, a commonly occurring heart valve disease.

Amgen introduces AMGEVITA in the European market

In October 2018, Amgen has reportedly publicised that AMGEVITA, an adalimumab biosimilar, will be launched in the European market. Reportedly, AMGEVITA claims that it is the world’s first adalimumab biosimilar to attain approval by the European Commission. AMGEVITA has been authorised for treating inflammatory conditions in adults and paediatric inflammations. AMGEVITA’s launch would cover 28 member countries of the European Union along with Liechtenstein, Iceland, and Norway.

Bio-Rad Laboratories unveils NGC Fraction Collector

Bio-Rad Laboratories Incorporation has reportedly unveiled the NGC Fraction Collector to be used for NGC Chromatography Systems. The NGC platform augments purification efficacy and offers researchers consummate control over the processes. The NGC Fraction Collector enables researchers to elect how to gather and when to address the fractions. Reportedly, the system could be prompted to collect on the basis of pH, buffer percent from pump B, slope, and detector indications. Front-to-back dispensing offers ease of access to fractions before process completion for quicker downstream examination. It operates on ChromLab™ 5.0 Software and ensures no sample loss through auto sample tube calculation.

It is thus rather discernible that biotechnology market is on its way to crop up as one of the most prominently remunerative business spheres. The growth projection for the biotechnology industry appears to be rather pronounced in the coming times, given the intensifying commercial consumption of this technology across an array of industries. As per estimates, biotechnology market size is poised to exceed a colossal $729bn by 2025.

Read more at our source, here.

Laboratory Supplies Directory - Now Live

LEAVE A REPLY

Please enter your comment!
Please enter your name here